MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement

MaxCyte has signed a strategic platform license agreement with Adicet Bio, granting non-exclusive rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. In return, MaxCyte will receive platform licensing fees and program-related revenue. The agreement aims to enhance the development of Adicet Bio's allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company, has signed a strategic platform license (SPL) agreement with Adicet Bio, Inc., a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform [1].

The agreement aims to enhance Adicet Bio's ability to develop and commercialize its gamma delta T cell therapies. MaxCyte's Flow Electroporation® technology and ExPERT™ platform are designed to support complex and scalable cell engineering, delivering high transfection efficiency and cell viability [2].

Maher Masoud, President and Chief Executive Officer of MaxCyte, stated, "We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery. This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility" [1].

MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement. However, the exact terms and conditions of the agreement, including the potential revenue streams, were not disclosed [1].

Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company's approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders [1].

The SPL agreement between MaxCyte and Adicet Bio is a significant step in advancing the development of next-generation cell therapies. It highlights the potential of MaxCyte's platform technology in enabling the efficient and scalable production of cell-based therapeutics [1].

References:
[1] https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-platform-license-agreement-adicet-bio
[2] https://www.morningstar.com/news/globe-newswire/9504081/maxcyte-signs-platform-license-agreement-with-adicet-bio